Comparative Pharmacology
Head-to-head clinical analysis: HAILEY 24 FE versus LOW OGESTREL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HAILEY 24 FE versus LOW OGESTREL 28.
HAILEY 24 FE vs LOW-OGESTREL-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone; inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol and norgestrel inhibit ovulation via suppression of gonadotropins (LH, FSH); increase viscosity of cervical mucus, impairing sperm penetration; alter endometrial structure, reducing implantation likelihood.
One tablet orally once daily for 24 weeks. Each tablet contains norethindrone 0.8 mg and ethinyl estradiol 0.02 mg. After 24 weeks, take one inactive (ferrous fumarate) tablet daily for 4 weeks. Total cycle: 28 tablets.
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 28 days, with 21 active tablets followed by 7 inactive tablets.
None Documented
None Documented
Ethinyl estradiol has a terminal half-life of approximately 13-27 hours (mean 18.5 hours). Norethindrone has a terminal half-life of approximately 8-12 hours. The half-life supports once-daily dosing.
Norgestrel: ~45 hours (terminal). Ethinyl estradiol: ~13 hours (terminal). Steady-state achieved within 5-7 days.
Ethinyl estradiol is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone is excreted in urine (30-50%) and feces (20-30%) as metabolites.
Renal 50-60% as metabolites, fecal 40-50% via biliary elimination. Ethinyl estradiol undergoes enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive